


This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (*currently amended*) A compound of formula I



wherein:

R and R¹ are independently H, A, OH, OA, OCH₂-Ar, Hal, NH₂, NHA, NA₂, NO₂, CN, C(O)R₂, CONHA, CONA₂, COOH, COOA or SO₂A,

R² and R³ are independently H, A, -C(=NH)-NH₂ or ~~a linking moiety attached an attachment~~ to a solid phase resin,

R⁴ is Ar, phenylalkyl, cycloalkyl or Het,

Y may be absent and, if present, is alkenyl having 2 to 4 carbon atoms,

A is unbranched or branched alkyl having 1 to 6 carbon atoms,

Ar is phenyl, naphthyl, biphenyl or benzofuranyl, which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂,

Het is a saturated, partially or completely unsaturated mono- or bicyclic heterocyclic radical having 5 to 10 ring members, where 1 or 2 N and/or 1 or 2 S or O atoms can be present and the heterocyclic radical can be mono- or disubstituted by A, Hal, OH, OA, CF₃, OCF₃, NH₂, NHA, NA₂, COOH, COOA, phenyl which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂ or thiophenyl which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂,

Hal is F, Cl, Br or I,
n is 1, 2 or 3,
m is 1, 2 or 3,
or a pharmaceutically tolerable salt or solvate thereof.


2. *(currently amended)* A compound ~~according to Claim 1~~ selected from the group consisting of:

- a) 3-(3-aminomethyl-cyclohexylmethyl)-2-[2,2']bithiophenyl-5-yl-6-methoxy-3H-quinazolin-4-one,
- b) 3-(3-aminomethyl-cyclohexylmethyl)-2-naphthalen-1-yl-6-methoxy-3H-quinazolin-4-one;
- c) 3-(3-aminomethyl-cyclohexylmethyl)-2-naphthalen-1-yl-6-methyl-3H-quinazolin-4-one;
- d) 3-(3-aminomethyl-cyclohexylmethyl)-2-naphthalen-1-yl-3H-quinazolin-4-one;
- e) 3-(3-aminomethyl-cyclohexylmethyl)-2-naphthalen-2-yl-6-methoxy-3H-quinazolin-4-one;
- f) 3-(3-aminomethyl-cyclohexylmethyl)-2-naphthalen-2-yl-3-H-quinazolin-4-one;
- g) 3-(3-aminomethyl-cyclohexylmethyl)-2-naphthalen-2-yl-6-methyl-3H-quinazolin-4-one;
- h) 3-(3-aminomethyl-cyclohexylmethyl)-6-chloro-2-naphthalen-2-yl-3H-quinazolin-4-one; and
- i) 3-(3-aminomethyl-cyclohexylmethyl)-7-chloro-2-naphthalen-2-yl-3H-quinazolin-4-one;

and physiologically acceptable salts and solvates thereof.

3. *(previously presented)* A process for preparing a compound of claim 1, comprising the step of: treating a solvate or hydrate of a compound of claim 1 with a solvolysing or hydrogenolysing agent

4. *(previously presented)* A pharmaceutical composition, comprising:
a compound according to Claim 1 or a pharmaceutically acceptable salt or solvate thereof; and a pharmaceutically acceptable excipient.
5. *(currently amended)* A method of antagonizing glycoprotein IbIX receptors, comprising the step of:
administering an effective amount of a compound ~~according to Claim 1 of~~ formula I



wherein:

R and R¹ are independently H, A, OH, OA, OCH₂-Ar, Hal, NH₂, NHA, NA₂, NO₂, CN, C(O)R₂, CONHA, CONA₂, COOH, COOA or SO₂A,

R² and R³ are independently H, A, -C(=NH)-NH₂ or an attachment to a solid phase resin,

R⁴ is Ar, phenylalkyl, cycloalkyl or Het,

Y may be absent and, if present, is alkenyl having 2 to 4 carbon atoms,

A is unbranched or branched alkyl having 1 to 6 carbon atoms,

Ar is phenyl, naphthyl, biphenyl or benzofuranyl, which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂,

Het is a saturated, partially or completely unsaturated mono- or bicyclic heterocyclic radical having 5 to 10 ring members, where 1 or 2 N and/or 1 or 2 S or O atoms can be present and the heterocyclic radical can be mono- or disubstituted by A, Hal, OH, OA, CF₃, OCF₃, NH₂, NHA, NA₂, COOH, COOA, phenyl which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF₃,

OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂ or thiophenyl which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂,

Hal is F, Cl, Br or I,

n is 1, 2 or 3,


m is 1, 2 or 3,

or a pharmaceutically acceptable salt or solvate thereof;

to a patient in need thereof.

6. (*currently amended*) A method of controlling a thrombotic disorder and sequelae deriving therefrom, comprising the step of:

administering an effective amount of a compound ~~according to Claim 1 of~~
formula I



wherein:

R and R¹ are independently H, A, OH, OA, OCH₂-Ar, Hal, NH₂, NHA, NA₂, NO₂, CN, C(O)R₂, CONHA, CONA₂, COOH, COOA or SO₂A,

R² and R³ are independently H, A, -C(=NH)-NH₂ or an attachment to a solid phase resin,

R⁴ is Ar, phenylalkyl, cycloalkyl or Het,

Y may be absent and, if present, is alkenyl having 2 to 4 carbon atoms,

A is unbranched or branched alkyl having 1 to 6 carbon atoms,

Ar is phenyl, naphthyl, biphenyl or benzofuranyl, which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂,

Het is a saturated, partially or completely unsaturated mono- or bicyclic heterocyclic radical having 5 to 10 ring members, where 1 or 2 N and/or 1 or 2 S or O atoms can be present and the heterocyclic radical can be mono- or disubstituted by A, Hal, OH, OA, CF₃, OCF₃, NH₂, NHA, NA₂, COOH, COOA, phenyl which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂ or thiophenyl which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂,

Hal is F, Cl, Br or I,

n is 1, 2 or 3,

m is 1, 2 or 3,


or a pharmaceutically acceptable salt or solvate thereof;

to a patient in need thereof.

7. *(cancelled)*

8. *(currently amended)* A method of preventing adhesion on a foreign surface in contact with a patient, comprising the step of:

administering an effective amount compound ~~according to Claim 1 of~~ formula I



wherein:

R and R¹ are independently H, A, OH, OA, OCH₂-Ar, Hal, NH₂, NHA, NA₂, NO₂, CN, C(O)R₂, CONHA, CONA₂, COOH, COOA or SO₂A,

R² and R³ are independently H, A, -C(=NH)-NH₂ or an attachment to a solid phase resin,

R⁴ is Ar, phenylalkyl, cycloalkyl or Het,

Y may be absent and, if present, is alkenyl having 2 to 4 carbon atoms,

A is unbranched or branched alkyl having 1 to 6 carbon atoms,

Ar is phenyl, naphthyl, biphenyl or benzofuranyl, which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂,

Het is a saturated, partially or completely unsaturated mono- or bicyclic heterocyclic radical having 5 to 10 ring members, where 1 or 2 N and/or 1 or 2 S or O atoms can be present and the heterocyclic radical can be mono- or disubstituted by A, Hal, OH, OA, CF₃, OCF₃, NH₂, NHA, NA₂, COOH, COOA, phenyl which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂ or thiophenyl which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CF₃, OCF₃, Hal, CN, COOH, COOA, NH₂, NHA, NA₂, NO₂, SO₂NH₂, SO₂NAH or SO₂NA₂,

Hal is F, Cl, Br or I,

n is 1, 2 or 3,


m is 1, 2 or 3,

or a pharmaceutically acceptable salt or solvate thereof;

to said patient.

9. *(previously presented)* A method according to claim 6, wherein said sequelae is myocardial infarct, arteriosclerosis, angina pectoris, acute coronary syndromes, peripheral circulatory disorders, stroke, transient ischaemic attacks, or reocclusion/restenosis after angioplasty/stent implantations.

10. *(previously presented)* A method according to claim 8, wherein said foreign surface is the surface of an implant, catheter, or heart pacemaker.
11. *(previously presented)* A process for forming a compound of claim 1 or a pharmaceutically tolerable salt or solvate thereof, comprising the steps of:
reacting a compound of formula II:




wherein:

X is Cl, Br, OH, or a reactive esterified OH group; and


Q is NH₂ or NHA, either of which is optionally protected, and

R and R¹ are optionally protected when they comprise NH₂ or NHA;

with a compound of formula III:



and optionally deprotecting said reaction product to form a compound of formula IV:



reacting said compound of formula IV with a compound of formula V:

DOCKET NO.: 3072003/3DP-0558
Application No.: 10/089,167
Office Action Dated: July 28, 2004

PATENT
REPLY FILED UNDER EXPEDITED
PROCEDURE PURSUANT TO
37 CFR § 1.116



to form a compound of claim 1 or a pharmaceutically tolerable salt or solvate thereof.